Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00886626 · ClinicalTrials.gov registry record · Phase 2
GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children
A Phase 2 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00886626 is a Phase 2 study that has completed, run by University of Minnesota. The registered enrollment target is 12 participants.
The verdict
NCT00886626, a Phase 2 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The prevalence of severely obese children is on the rise. Behavioral therapies for weight loss are successful in some, but others need more aggressive approaches such as drug therapy. In addition, up to 25% of severely obese children have impaired glucose tolerance (IGT), which places them at significantly elevated risk of developing type 2 diabetes mellitus and cardiovascular disease. Although various drug therapies for weight loss and IGT have been explored in adults, few have been evaluated in children. Recently, a new drug class has emerged that targets deficiencies of GLP-1. One of the main glycemic mechanisms of action of the GLP-1 agonists such as exenatide is to enhance glucose disposal in the postprandial setting and improve glucose tolerance. In addition, exenatide can induce weight loss by decreasing appetite and slowing gastric motility.
Interventions
- DRUG Exenatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-05 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00886626
The ClinicalTrials.gov registry entry for NCT00886626 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Exenatide is the first listed.
NCT00886626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00886626 about?
NCT00886626 is a clinical study titled "GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children". The prevalence of severely obese children is on the rise. Behavioral therapies for weight loss are successful in some, but others need more aggressive approaches such as drug therapy. In addition, up to 25% of severely obese children have impaired glucose tolerance (IGT), which places them at signif...
What is the current status of trial NCT00886626?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2009-05. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00886626?
The interventions under investigation include: Exenatide (DRUG).
Who is sponsoring clinical trial NCT00886626?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.